BR112012011784A2 - "formulações parenterais de derivados de gencitabina". - Google Patents

"formulações parenterais de derivados de gencitabina".

Info

Publication number
BR112012011784A2
BR112012011784A2 BR112012011784A BR112012011784A BR112012011784A2 BR 112012011784 A2 BR112012011784 A2 BR 112012011784A2 BR 112012011784 A BR112012011784 A BR 112012011784A BR 112012011784 A BR112012011784 A BR 112012011784A BR 112012011784 A2 BR112012011784 A2 BR 112012011784A2
Authority
BR
Brazil
Prior art keywords
gemcitabine
derivatives
parenteral formulations
relates
present
Prior art date
Application number
BR112012011784A
Other languages
English (en)
Inventor
Myhren Finn
Henrik Eriksen Ole
Ahrabi Sayeh
Original Assignee
Clavis Pharma Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clavis Pharma Asa filed Critical Clavis Pharma Asa
Publication of BR112012011784A2 publication Critical patent/BR112012011784A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

formulações parenterais de derivados de gencitabina. a presente invenção refere-se a formulações parenterais para certos derivados de ácido graxo saturado e monoinsaturado de cadeia longa de 2',2'-difluorodesoxicitidina (gencitabina). em particular, a presente invenção se refere a uma composição farmacêutica parenteral e um método da sua preparação, a fim de acomodar doses terapeuticamente eficazes dos referidos derivados melhorando a complacência no tratamento do câncer. a composição tem um tamanho de partícula médio na faixa de 2,5-30 nm e tipicamente contém um fosfolipídeo. um ingrediente ativo preferido é gencitabina-5'-éster de ácido elaídico.
BR112012011784A 2009-11-20 2010-11-15 "formulações parenterais de derivados de gencitabina". BR112012011784A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26299909P 2009-11-20 2009-11-20
PCT/NO2010/000417 WO2011062503A1 (en) 2009-11-20 2010-11-15 Parenteral formulations of gemcitabine derivatives

Publications (1)

Publication Number Publication Date
BR112012011784A2 true BR112012011784A2 (pt) 2019-09-24

Family

ID=43467050

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011784A BR112012011784A2 (pt) 2009-11-20 2010-11-15 "formulações parenterais de derivados de gencitabina".

Country Status (13)

Country Link
US (1) US20110281815A1 (pt)
EP (1) EP2501364A4 (pt)
JP (1) JP2013511516A (pt)
KR (1) KR20120086729A (pt)
CN (1) CN102740833A (pt)
AU (1) AU2010322516A1 (pt)
BR (1) BR112012011784A2 (pt)
CA (1) CA2778432A1 (pt)
GB (1) GB201019703D0 (pt)
MX (1) MX2012005677A (pt)
RU (1) RU2012125350A (pt)
TW (1) TW201124425A (pt)
WO (1) WO2011062503A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US20130122096A1 (en) 2011-11-14 2013-05-16 Silenseed Ltd. Compositions for drug delivery and methods of manufacturing and using same
US9006199B2 (en) 2011-11-14 2015-04-14 Silenseed Ltd. Methods and compositions for treating prostate cancer
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
US8889642B2 (en) 2012-04-19 2014-11-18 Silenseed Ltd. Methods and compositions for RNAi-based cancer treatment
BR112015010941A2 (pt) 2012-11-13 2017-07-11 Boyen Therapeutics Inc pró-fármacos de gemcitabina e suas utilizações
WO2015069926A1 (en) 2013-11-06 2015-05-14 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
RS61273B1 (sr) 2014-04-30 2021-01-29 Fujifilm Corp Lipozomska kompozicija i postupak za njeno dobijanje
ES2655820T3 (es) 2014-06-25 2018-02-21 NuCana plc Formulación que comprende un profármaco de gemcitabina
WO2015198058A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
WO2017201528A1 (en) 2016-05-20 2017-11-23 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
JP2020520961A (ja) 2017-05-24 2020-07-16 サイレンシード リミテッド がん免疫療法のための組成物及び方法
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
CN113616618B (zh) * 2017-09-22 2022-11-08 杭州景杰生物科技股份有限公司 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒
CA3104084C (en) * 2018-06-20 2023-08-01 Fujifilm Corporation Combined pharmaceutical formulation comprising gemcitabine-containing liposome composition and immune checkpoint inhibitor
CN109998996B (zh) * 2019-05-05 2021-02-26 中国医学科学院医药生物技术研究所 脂质组合物及提高药物抗肿瘤活性的方法
CN112898277B (zh) * 2019-11-19 2022-04-22 扬子江药业集团有限公司 一种阿法替尼中间体的制备方法
CN111249252B (zh) * 2020-03-08 2021-09-14 中国医学科学院医药生物技术研究所 白蛋白纳米粒组合物及其制法
CN113307824B (zh) 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用
EP4248949B1 (en) 2022-03-21 2024-08-28 R.G.C.C. Holdings AG Liposomal compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
DE69812934T2 (de) * 1997-01-24 2004-01-29 Conpharma As Oslo Gemcitabin-derivate
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
WO2010039039A1 (en) * 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives

Also Published As

Publication number Publication date
KR20120086729A (ko) 2012-08-03
AU2010322516A1 (en) 2012-05-17
US20110281815A1 (en) 2011-11-17
RU2012125350A (ru) 2013-12-27
JP2013511516A (ja) 2013-04-04
CN102740833A (zh) 2012-10-17
CA2778432A1 (en) 2011-05-26
EP2501364A4 (en) 2012-10-24
MX2012005677A (es) 2012-08-23
EP2501364A1 (en) 2012-09-26
WO2011062503A1 (en) 2011-05-26
GB201019703D0 (en) 2011-01-05
TW201124425A (en) 2011-07-16

Similar Documents

Publication Publication Date Title
BR112012011784A2 (pt) "formulações parenterais de derivados de gencitabina".
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
BRPI0922804B8 (pt) composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável
JP2020522514A5 (pt)
KR102274963B1 (ko) 15-hepe를 포함하는 조성물 및 그의 사용 방법
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
CA3146071A1 (en) Preparation comprising omega-3 fatty acid salts and extracts of gum resins from boswellia species
JP2018517666A5 (pt)
JP6280535B2 (ja) Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物
HRP20190660T1 (hr) FORMULACIJA N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOHINOLIN-3-KARBOKSAMIDA U OBLIKU TABLETE ZA UPOTREBU U TRETMANU CISTIČNE FIBROZE
CO6300930A2 (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos
BRPI1015120B8 (pt) Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico
AR061289A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ZA201005615B (en) Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112023021160A2 (pt) Lipídeos ionizáveis e composições para liberação em ácido nucleico
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
KR20150055024A (ko) 이데베논, n-아세틸-s-파네실-l-씨스테인 및 에르고티오네인으로 구성되는 제제와 그 용도
BR112012018765A2 (pt) agente profilático ou terapêutico para as doenças do trato biliar
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
Ali et al. Recent advances in the pharmacological properties and molecular mechanisms of carvacrol
Raghavendra et al. Eugenol and n-3 rich garden cress seed oil as modulators of platelet aggregation and eicosanoids in Wistar albino rats
WO2015020186A1 (ja) 錠剤組成物
BR112012028787A2 (pt) lipossomos terapêuticos e métodos para produzir e usar os mesmos
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.